News Releases

Sep 17, 2020
Applied Therapeutics to Present Data on AT-001 for Treatment of Diabetic Cardiomyopathy at 56th Annual Meeting of the European Association for the Study of Diabetes
NEW YORK , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present two
Additional Formats
Sep 02, 2020
Applied Therapeutics to Present at Citi and Baird Investor Conferences
NEW YORK , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at
Additional Formats
Aug 11, 2020
Applied Therapeutics Reports Second Quarter 2020 Financial Results
NEW YORK , Aug. 11, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the
Additional Formats
Jun 08, 2020
Applied Therapeutics to Present Data on AT-001 for the Treatment of Diabetic Cardiomyopathy at 2020 American Diabetes Association Virtual Scientific Sessions
NEW YORK , June 08, 2020 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that three abstracts have
Additional Formats
Displaying 1 - 10 of 22